{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:01:16Z","timestamp":1789189276121,"version":"build-2803163510"},"reference-count":84,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III MINECO and Peder Funds","doi-asserted-by":"publisher","award":["PI21\/00315"],"award-info":[{"award-number":["PI21\/00315"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III MINECO and Peder Funds","doi-asserted-by":"publisher","award":["2020\/0142"],"award-info":[{"award-number":["2020\/0142"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario Ram\u00f3n y Cajal","award":["PI21\/00315"],"award-info":[{"award-number":["PI21\/00315"]}]},{"name":"Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario Ram\u00f3n y Cajal","award":["2020\/0142"],"award-info":[{"award-number":["2020\/0142"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cutaneous cancers are, by far, the most common malignant neoplasms of the human being. Due to the great array of clinical conditions, their worldwide increasing incidence and the steady ageing of the population, non-invasive treatments modalities that show a good clinical response, a proper benefit\u2013risk ratio and cosmetic results are becoming increasingly important in the clinical setting. Imiquimod is a topically applied immunomodulator which is often used in the management of several premalignant and malignant cutaneous disorders. This article is a review of the current literature on its mechanism of action, pharmacokinetics, and therapeutical effects.<\/jats:p>","DOI":"10.3390\/ijms241310835","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:41:45Z","timestamp":1687999305000},"page":"10835","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-8361","authenticated-orcid":false,"given":"Emilio","family":"Garcia-Mouronte","sequence":"first","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-5421","authenticated-orcid":false,"given":"Emilio","family":"Berna-Rico","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"de Nicolas-Ruanes","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Azcarraga-Llobet","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Alonso-Martinez de Salinas","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Bea-Ardebol","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.det.2004.08.007","article-title":"Imiquimod for the Treatment of Skin Cancer","volume":"23","author":"Burns","year":"2005","journal-title":"Dermatol. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.det.2019.05.003","article-title":"Nonsurgical Treatments for Nonmelanoma Skin Cancer","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_3","first-page":"CD003412","article-title":"Interventions for Basal Cell Carcinoma of the Skin","volume":"11","author":"Thomson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/imt.12.29","article-title":"Immunotherapy in Nonmelanoma Skin Cancer","volume":"4","year":"2012","journal-title":"Immunotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00128071-200405060-00010","article-title":"Role of Imiquimod in Skin Cancer Treatment","volume":"5","author":"Urosevic","year":"2004","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.addr.2019.11.002","article-title":"Topical Treatments for Skin Cancer","volume":"153","author":"Cullen","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.36849\/JDD.5427","article-title":"A Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers","volume":"20","author":"Nahm","year":"2021","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clindermatol.2017.10.009","article-title":"Nonsurgical Treatment of Nonmelanoma Skin Cancer in the Mature Patient","volume":"36","author":"Mokos","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_9","first-page":"170","article-title":"Optical Coherence Tomography Imaging of Non-Melanoma Skin Cancer Undergoing Imiquimod Therapy","volume":"20","author":"Banzhaf","year":"2014","journal-title":"Skin Res. Technol. Off. J. Int. Soc. Bioeng. Skin ISBS Int. Soc. Digit. Imaging Skin ISDIS Int. Soc. Skin Imaging ISSI"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jdermsci.2011.11.001","article-title":"Mcl-1 Determines the Imiquimod-Induced Apoptosis but Not Imiquimod-Induced Autophagy in Skin Cancer Cells","volume":"65","author":"Huang","year":"2012","journal-title":"J. Dermatol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/14656566.2010.481284","article-title":"Treating Skin Cancer with Topical Cream","volume":"11","author":"Micali","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.clindermatol.2013.08.020","article-title":"Non-Melanoma Skin Cancers: Photodynamic Therapy, Cryotherapy, 5-Fluorouracil, Imiquimod, Diclofenac, or What? Facts and Controversies","volume":"31","author":"Bahner","year":"2013","journal-title":"Clin. Dermatol."},{"key":"ref_13","first-page":"450","article-title":"Before or after: Is There a Connection between the Use of Adjunctive Nonmelanoma Skin Cancer Treatments and Subsequent Invasive Tumors?","volume":"14","author":"Ruiz","year":"2015","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1517\/14656566.8.11.1743","article-title":"Imiquimod: An Immune Response Modifier in the Treatment of Precancerous Skin Lesions and Skin Cancer","volume":"8","author":"Papadavid","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Work Group, Invited Reviewers, Kim, J.Y.S., Kozlow, J.H., Mittal, B., Moyer, J., Olencki, T., and Rodgers, P. (2018). Guidelines of Care for the Management of Basal Cell Carcinoma. J. Am. Acad. Dermatol., 78, 540\u2013559.","DOI":"10.1016\/j.jaad.2017.10.006"},{"key":"ref_16","first-page":"10","article-title":"Diagnosis and Treatment of Basal Cell Carcinoma: European Consensus-Based Interdisciplinary Guidelines","volume":"118","author":"Peris","year":"2019","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000502470","article-title":"Evidence-Based Clinical Practice Guidelines for the Management of Patients with Lentigo Maligna","volume":"236","author":"Robinson","year":"2020","journal-title":"Dermatol. Basel Switz."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","article-title":"Guidelines of Care for the Management of Actinic Keratosis","volume":"85","author":"Eisen","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2165\/00003495-200666130-00001","article-title":"The Role of Topical Immune Response Modifiers in Skin Cancer","volume":"66","author":"Woodmansee","year":"2006","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e15326","DOI":"10.1111\/dth.15326","article-title":"Imiquimod-Side Effects in the Treatment of Periocular Skin Cancers: A Review of the Literature","volume":"35","author":"Avallone","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D328458526","article-title":"Imiquimod-Induced Hypertrophic Lupus Erythematosus-like Reaction","volume":"28","author":"Safadi","year":"2022","journal-title":"Dermatol. Online J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13517","DOI":"10.1111\/dth.13517","article-title":"Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream: Two Case Reports-Perspective for Non Melanoma Skin Cancer Prevention","volume":"33","author":"Kopera","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jdermsci.2020.03.009","article-title":"Imiquimod-Induced ROS Production Disrupts the Balance of Mitochondrial Dynamics and Increases Mitophagy in Skin Cancer Cells","volume":"98","author":"Chuang","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000069957","article-title":"Nudging Epidermal Field Cancerogenesis by Imiquimod","volume":"206","author":"Uhoda","year":"2003","journal-title":"Dermatol. Basel Switz."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.1038\/s41598-019-42784-9","article-title":"Transcriptomic Profiles Conducive to Immune-Mediated Tumor Rejection in Human Breast Cancer Skin Metastases Treated with Imiquimod","volume":"9","author":"Rozenblit","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.0366-077X.2003.05634.x","article-title":"Expression of Fas-Receptor on Basal Cell Carcinomas after Treatment with Imiquimod 5% Cream or Vehicle","volume":"149","author":"Berman","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jdermsci.2022.08.006","article-title":"Imiquimod-Induced ROS Production Causes Lysosomal Membrane Permeabilization and Activates Caspase-8-Mediated Apoptosis in Skin Cancer Cells","volume":"107","author":"Chang","year":"2022","journal-title":"J. Dermatol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14728222.10.1.69","article-title":"The Small-Molecule Immune Response Modifier Imiquimod--Its Mode of Action and Clinical Use in the Treatment of Skin Cancer","volume":"10","year":"2006","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/djg016","article-title":"Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod","volume":"95","author":"Bong","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D36DM013FJ","article-title":"Local Reactions to Imiquimod in the Treatment of Basal Cell Carcinoma","volume":"18","author":"Tandon","year":"2012","journal-title":"Dermatol. Online J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.det.2019.02.004","article-title":"Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer","volume":"37","author":"Nemer","year":"2019","journal-title":"Dermatol. Clin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1365-2133.2002.05069.x","article-title":"Imiquimod 5% Cream for the Treatment of Superficial and Nodular Basal Cell Carcinoma: Randomized Studies Comparing Low-Frequency Dosing with and without Occlusion","volume":"147","author":"Sterry","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-0-387-78574-5_20","article-title":"Actinic Keratoses","volume":"146","author":"Stockfleth","year":"2009","journal-title":"Cancer Treat. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8369690","DOI":"10.1155\/2019\/8369690","article-title":"Mediators of Inflammation in Topical Therapy of Skin Cancers","volume":"2019","author":"Voiculescu","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"24932","DOI":"10.18632\/oncotarget.15326","article-title":"The TLR7 Agonist Imiquimod Induces Anti-Cancer Effects via Autophagic Cell Death and Enhances Anti-Tumoral and Systemic Immunity during Radiotherapy for Melanoma","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sisti, A., Sisti, G., and Oranges, C.M. (2015). Topical Treatment of Melanoma Skin Metastases with Imiquimod: A Review. Dermatol. Online J., 21.","DOI":"10.5070\/D3212023034"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% Cream for the Treatment of Actinic Keratosis: Results from a Phase III, Randomized, Double-Blind, Vehicle-Controlled, Clinical Trial with Histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/bjd.15112","article-title":"Dermatology Clinical Trials Network and the LIMIT-1 Collaborative Group. Effect of Topical Imiquimod as Primary Treatment for Lentigo Maligna: The LIMIT-1 Study","volume":"176","author":"Marsden","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_39","first-page":"778","article-title":"The Treatment of Actinic Keratoses with a Combination of 5-Fluorouracil and Imiquimod Creams","volume":"6","author":"Price","year":"2007","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","article-title":"Vehicle-controlled, Randomized, Double-blind Study to Assess Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days per Week in One or Two Courses of Treatment of Actinic Keratoses on the Head","volume":"157","author":"Alomar","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/09546630310019373","article-title":"Imiquimod 5% Cream in the Treatment of Mycosis Fungoides\u2014A Pilot Study","volume":"15","author":"Chong","year":"2004","journal-title":"J. Dermatol. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajd.13447","article-title":"A Review of Actinic Keratosis, Skin Field Cancerisation and the Efficacy of Topical Therapies","volume":"62","author":"Sinclair","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/09546634.2019.1682504","article-title":"Contemporary Management of Actinic Keratosis","volume":"32","author":"Marghoob","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/jamadermatol.2022.1034","article-title":"Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial","volume":"158","author":"Ahmady","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jdv.12538","article-title":"Photodynamic Therapy vs. Imiquimod 5% Cream as Skin Cancer Preventive Strategies in Patients with Field Changes: A Randomized Intraindividual Comparison Study","volume":"29","author":"Sotiriou","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1046\/j.1440-0960.2003.00003.x","article-title":"Short-Course Therapy with Imiquimod 5% Cream for Solar Keratoses: A Randomized Controlled Trial","volume":"44","author":"Chen","year":"2003","journal-title":"Australas. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2133.2009.09260.x","article-title":"Effect of Dosing Frequency on the Safety and Efficacy of Imiquimod 5% Cream for Treatment of Actinic Keratosis on the Forearms and Hands: A Phase II, Randomized Placebo-Controlled Trial","volume":"161","author":"Gebauer","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","article-title":"Imiquimod 2.5% and 3.75% for the Treatment of Actinic Keratoses: Results of Two Placebo-Controlled Studies of Daily Application to the Face and Balding Scalp for Two 3-Week Cycles","volume":"62","author":"Hanke","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-Controlled, Double-Blind, Randomized Study of Imiquimod 5% Cream Applied 3 Days per Week in One or Two Courses of Treatment for Actinic Keratoses on the Head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% Imiquimod Cream 3 Times per Week for the Treatment of Actinic Keratosis: Results of Two Phase 3, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/archderm.138.11.1498","article-title":"A Randomized, Double-Blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses","volume":"138","author":"Stockfleth","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/1346-8138.12310","article-title":"Comparative Study for the Effect of Photodynamic Therapy, Imiquimod Immunotherapy and Combination of Both Therapies on 40 Lesions of Actinic Keratosis in Japanese Patients","volume":"40","author":"Tanaka","year":"2013","journal-title":"J. Dermatol."},{"key":"ref_53","first-page":"35","article-title":"Treatment of Actinic Keratoses with Sequential Use of Photodynamic Therapy; and Imiquimod 5% Cream","volume":"8","author":"Shaffelburg","year":"2009","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"486","DOI":"10.36849\/JDD.7334","article-title":"Keratinocyte Carcinoma Chemoprevention With a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin","volume":"22","author":"Nahm","year":"2023","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_55","first-page":"1101","article-title":"A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Efficacy and Safety Study of 3.75% Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses","volume":"9","author":"Jorizzo","year":"2010","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_56","first-page":"36","article-title":"Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma","volume":"44","author":"Bostanci","year":"2018","journal-title":"Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg. Al"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1067\/mjd.2002.126215","article-title":"Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma: A Double-Blind, Randomized, Vehicle-Controlled Study","volume":"47","author":"Geisse","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1365-2133.2005.06486.x","article-title":"Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma: Results from a Randomized Vehicle-Controlled Phase III Study in Europe","volume":"152","author":"Schulze","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1067\/mjd.2001.113689","article-title":"Australasian Multicentre Trial Group Imiquimod 5% Cream in the Treatment of Superficial Basal Cell Carcinoma: Results of a Multicenter 6-Week Dose-Response Trial","volume":"44","author":"Marks","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09546630701557965","article-title":"A Randomized Parallel Study to Assess the Safety and Efficacy of Two Different Dosing Regimens of 5% Imiquimod in the Treatment of Superficial Basal Cell Carcinoma","volume":"19","author":"Ezughah","year":"2008","journal-title":"J. Dermatol. Treat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaad.2007.05.022","article-title":"A Phase III, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Imiquimod 5% Cream Applied Thrice Weekly for 8 and 12 Weeks in the Treatment of Low-Risk Nodular Basal Cell Carcinoma","volume":"57","author":"Eigentler","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1468-3083.2011.04177.x","article-title":"A Pilot Study of Clinical Efficacy of Imiquimod and Cryotherapy for the Treatment of Basal Cell Carcinoma with Incomplete Response to Imiquimod","volume":"26","author":"Messeguer","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_63","first-page":"63","article-title":"Pilot Study of Imiquimod 5% Cream as Adjunctive Therapy to Curettage and Electrodesiccation for Nodular Basal Cell Carcinoma","volume":"32","author":"Spencer","year":"2006","journal-title":"Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg. Al"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/jocd.14354","article-title":"The Combined Effect of CO2 Laser, Topical Diclofenac 3%, and Imiquimod 5% in Treating High-Risk Basal Cell Carcinoma","volume":"21","author":"Saudi","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jaad.2020.04.053","article-title":"Surgery versus Combined Treatment with Curettage and Imiquimod for Nodular Basal Cell Carcinoma: One-Year Results of a Noninferiority, Randomized, Controlled Trial","volume":"83","author":"Sinx","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.sder.2010.10.002","article-title":"Managing Melanoma in Situ","volume":"29","author":"Toren","year":"2010","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"XV","DOI":"10.1111\/j.0022-202X.2004.22537.x","article-title":"Imiquimod: Unexpected Killer","volume":"122","author":"Leverkus","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2015.05.022","article-title":"A Quantitative Systematic Review of the Efficacy of Imiquimod Monotherapy for Lentigo Maligna and an Analysis of Factors That Affect Tumor Clearance","volume":"73","author":"Mora","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/jdv.14085","article-title":"A Systematic Review on the Role of Imiquimod in Lentigo Maligna and Lentigo Maligna Melanoma: Need for Standardization of Treatment Schedule and Outcome Measures","volume":"31","author":"Tio","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_70","first-page":"555","article-title":"Novel Treatment of In-Transit Metastatic Melanoma with Shave Excision, Electrodesiccation and Curettage, and Topical Imiquimod 5% Cream","volume":"20","author":"Globerson","year":"2021","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0025-7125(16)31889-2","article-title":"Intralesional Immunotherapy of Melanoma with BCG","volume":"60","author":"Rosenberg","year":"1976","journal-title":"Med. Clin. N. Am."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II Trial of Intralesional Therapy with Interleukin-2 in Soft-Tissue Melanoma Metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s10637-011-9717-2","article-title":"Topical Treatment of Cutaneous Metastases of Malignant Melanoma Using Combined Imiquimod and 5-Fluorouracil","volume":"30","author":"Florin","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2006.07664.x","article-title":"Phase I\/II Study of Topical Imiquimod and Intralesional Interleukin-2 in the Treatment of Accessible Metastases in Malignant Melanoma","volume":"156","author":"Green","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1200\/JCO.2012.46.4883","article-title":"Imiquimod in the Treatment of Breast Cancer Skin Metastasis","volume":"32","author":"Henriques","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_76","first-page":"305","article-title":"Extramammary Paget\u2019s Disease: A Review of the Literature Part II: Treatment and Prognosis","volume":"46","author":"Morris","year":"2020","journal-title":"Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg. Al"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/1346-8138.14117","article-title":"Imiquimod 5% Cream as a Therapeutic Option for Extramammary Paget\u2019s Disease","volume":"45","author":"Sawada","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2016.04.028","article-title":"A Pilot Study of Topical Imiquimod Therapy for the Treatment of Recurrent Extramammary Paget\u2019s Disease","volume":"142","author":"Cowan","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/CCID.S273063","article-title":"Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice","volume":"15","author":"Roccuzzo","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jdcr.2015.08.007","article-title":"Clearance of Folliculotropic and Tumor Mycosis Fungoides with Topical 5% Imiquimod","volume":"1","author":"Gordon","year":"2015","journal-title":"JAAD Case Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2004.04.049","article-title":"Treatment of Patch and Plaque Stage Mycosis Fungoides with Imiquimod 5% Cream","volume":"52","author":"Deeths","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jdv.12718","article-title":"Treatment of Localized Pagetoid Reticulosis with Imiquimod: A Case Report and Literature Review","volume":"30","author":"Su","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2133.2006.07599.x","article-title":"Solitary Plaque Mycosis Fungoides on the Penis Responding to Topical Imiquimod Therapy","volume":"156","author":"Chiam","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archderm.141.8.985","article-title":"Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients: Randomized, Double-Blind, Placebo-Controlled Trial","volume":"141","author":"Brown","year":"2005","journal-title":"Arch. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10835\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:20Z","timestamp":1760126600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":84,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310835"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310835","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}